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HIV and schistosomiasis co-infection in African children
Amaya Bustinduy, Charles King, Janet Scott, Sarah Appleton, José Carlos Sousa-Figueiredo, Martha Betson, J Russell Stothard
HIV/AIDS and schistosomiasis both cause a substantial disease burden in sub-Saharan Africa and the two diseases often 
overlap in their epidemiological characteristics. Although disease-speciﬁ c control interventions are continuing, potential 
synergies in the control eﬀ orts for these two diseases have not been investigated. With a focus on children with 
schistosomiasis, we assess the risk for increased HIV transmission, HIV progression, and impaired response to drugs 
when given alongside HIV interventions. A new research agenda tailored to children is needed to better understand the 
interactions of these two diseases and the potential for combined responses. 
Introduction
HIV and schistosomiasis are two of the most widespread 
infections worldwide; nonetheless, their combined eﬀ ect 
has not been fully delineated, especially in sub-Saharan 
Africa. Although both diseases diﬀ er in their presentation, 
manifestations, and treatment, there is substantial geo-
graphical overlap in the poorest countries where 
endemicity is often high (ﬁ gure 1).1 For example, in 
Ethiopia, Nigeria, South Africa, Zambia, and Zimbabwe, 
adult HIV prevalence ranges from 15% to 28%, and the 
prevalence of schistosomiasis commonly exceeds 50% in 
high-risk rural communities.2 The prevalence of HIV and 
schistosomiasis might be even higher in data-deﬁ cient 
areas such as Madagascar or Mozambique.3 
As the HIV pandemic progresses, interventions against 
the increase in HIV-related disease have focused on 
universal access to antiretroviral therapy (ART). Many 
children in sub-Saharan Africa present for care late in their 
HIV disease progression,4 and there are nearly 1000 new 
cases of paediatric HIV infection every day—more than 
2·5 million children younger than 15 years have 
HIV/AIDS.3 WHO guidance5,6 emphasises the importance 
of prompt diagnosis, treatment, and monitoring of HIV in 
children. Although there is a strong commitment from the 
international community to eliminate new childhood HIV 
infections by 2015, the HIV epidemic in sub-Saharan 
Africa shows little sign of abatement.7
Schistosomiasis, either urogenital or intestinal, is a 
chronic inﬂ ammatory disease caused by a water-borne 
parasitic blood ﬂ uke. In sub-Saharan Africa, 220 million 
people are infected with the parasite, and even more are 
at risk, mainly children.2 Although congenital trans-
mission does not occur, exposure and infection can take 
place very soon after birth, depending on an infant’s 
environmental exposure to parasite-infested water. Until 
recently, the burden of disease from these early 
exposures was overlooked. However, infants and 
preschool-age children (aged 1–5 years) can have active 
disease8,9 and have poor access to deworming treatment 
because current measures are focused on preventive 
chemotherapy (ie, mass drug administration of 
praziquantel to school-age children aged 6–15 years).10 
Praziquantel is a safe and aﬀ ordable oral drug that is 
active against all forms of schistosomiasis and can be 
given by non-medical personnel.11 As new information 
emerges about schistosomiasis in early childhood, 
international policies and practices are beginning to 
respond to this unmet need.12,13
Identiﬁ cation of disconnects in combined control
HIV control has only a short history, whereas schisto-
somiasis is an old disease14 for which the inability to 
implement fully integrated preventive strategies because 
of shortfalls in water hygiene and sanitation has led to 
the dominance of preventive chemotherapy as the most 
cost-eﬀ ective option of control. Locally applicable and 
integrated interventions tailored to the immediate 
epidemiological setting are desirable. Intricate under-
standing of the transmission biology, epidemiology, and 
social patterning (ie, HIV largely by sexual behaviour and 
schistosomiasis by water contact) of the diseases is 
needed.
Environmental risk factors for both infections include 
insuﬃ  cient access to safe water, low socioeconomic status, 
and poor educational access.15 HIV transmission risk is 
made up of complex individual behaviours, including 
commercial sex work, intravenous drug use, and various 
unsafe exposures to blood and other bodily ﬂ uids; in sub-
Saharan Africa lack of autonomy for women and 
intolerance of male homosexuality are important factors.16 
The social context of schistosomiasis is very diﬀ erent, but 
relates to unsafe exposures that are repeated often during 
domestic tasks or employment. Schistosomiasis is 
typically highly prevalent in ﬁ shing communities in which 
opportunities for HIV transmission can also be raised.15,17 
To further complicate control, each disease agent has 
ecological and genetic diversity, with potential to adapt to 
control interventions.18
Although multidisease approaches are being promoted 
by WHO (eg, in management of HIV and malaria), 
related platforms for research and operational control of 
HIV and schistosomiasis simply do not exist.19 There is 
also little room for future optimism because the newly 
created Disease Reference Group of Helminthic 
Infections for the control and elimination of 
helminthiasis in people has not adopted a multiple-
endemic-disease approach within their framework.18 
The ﬁ rst cases of HIV/AIDS in adults were described in 
1981,20 and 5 years lapsed before evidence of routes other 
than sexual transmission emerged and paediatric 
HIV/AIDS was recognised.21 The importance of mother-to-
child transmission of HIV has only slowly become a public 
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health priority.7 Alongside this focus, and with much less 
political advocacy, the case for prevention of schistosomiasis 
in early childhood is only now beginning.8,22–24 Moreover, as 
the subtly disabling morbidities associated with chronic 
schistosomiasis in this age group are being better 
recognised, an imperative for early prevention and control 
is becoming much clearer.25–29
Both diseases are diﬃ  cult to diagnose in early 
childhood, and studies of HIV and schistosomiasis co-
infection have been limited to adults.30,31 Paediatric 
studies (except for maternal–child health research) 
typically lag behind those in adults,32 and estimation of 
true burden of disease becomes a challenge because of 
an absence of paediatric diagnostics in resource-poor 
areas (appendix p 1).33 
Reconnection of the importance of HIV and 
schistosomiasis co-infection 
Given the potentially overwhelming burden of disease 
caused by dual infection, there are growing eﬀ orts to study 
the interactions between HIV and schistosomiasis, 
especially in areas where dual endemicity is most 
prevalent.34–37 Researchers doing experimental studies in 
animals are trying to understand the pathogenesis and 
immune responses when both infections are present.38,39 
Investigators have carried out clinical studies of responses 
to antiparasitic and ART for HIV/AIDS disease 
progression.40–43 However, all of these clinical studies 
exclusively targeted individuals older than 18 years, and 
thereby overlooked interactions in childhood. Attempting 
to bridge this knowledge gap for childhood HIV and 
schistosomiasis co-infection, we reviewed the most 
relevant epidemiological and experi mental studies to 
develop a conceptual framework (ﬁ gure 2) that identiﬁ es 
the transmission and later mani festations of disease in 
early life alongside current recommendations for 
treatment and integrated national control programmes.
Vertical HIV transmission 
The close associations between mothers and their 
unborn children begin an intricate interplay of antigen 
exposure and immune-response modiﬁ cation that 
continues throughout childhood. This interplay might 
lead to increased susceptibility to certain diseases and 
decreased cognition; all of which are known downstream 
eﬀ ects in children born to women with malaria or 
advanced HIV,26,44,45 but are not yet known in children 
born to women with both HIV and schistosomiasis. 
Risk for transmission from infected mothers to children 
ranges from 15–45%, depending on breastfeeding 
practices.46 Prepartum maternal helminth infections 
have been linked to increased mother-to-child 
transmission of HIV,47 but lesions from female genital 
schistosomiasis are possibly important also.
WHO advocates universal ART of all pregnant women 
with HIV, irrespective of their CD4 cell counts, but this 
target is far from a reality in resource-poor sub-Saharan 
Africa.7 The lack of consistent ART for pregnant women is 
one of the major hurdles to controlling HIV transmission. 
Alongside ART, antiparasitic treatment (with praziquantel, 
albendazole, or ivermectin) has the possible beneﬁ cial 
eﬀ ect of lowering HIV viral load.48 However, the researchers 
who reported this beneﬁ t did not ﬁ nd consistent ART 
availability for participants and future studies should adopt 
full treatment of HIV and parasites as standard. 
Diﬀ erences between children and adults
Extrapolation of knowledge and recommendations from 
adult health interventions into paediatric settings often 
Schistosomiasis
High (prevalence ≥50%)
Moderate (prevalence 10–49%)
Low (prevalence <10%)
Countries requiring evaluation of schistosomiasis status
to verify if interruption of transmission has been achieved
Non-endemic countries
Not applicable 
HIV
15·0–28·0%
5·0–14·9%
1·0–4·9%
0·5–0·9%
0·1–0·4%
<0·1%
No data available
Figure 1: Global adult prevalence of HIV and schistosomiasis 
Diﬀ erent forms of schistosomiasis—urogenital and intestinal—are aggregated, including those aﬀ ecting adults 
and school-age children. Dual schistosome infections have not yet been fully estimated nor are prevalences of co-
infections with HIV known. Data from WHO. 
See Online for appendix
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has a so-called little adults approach. For HIV and 
schistosomiasis co-infection, this approach is especially 
ﬂ awed in research and policy. For example, children 
have a larger surface-to-volume ratio with higher 
metabolic rate, oxygen consumption, and caloric 
requirements than have adults, not only to maintain 
homoeostasis, but also to grow and develop. Typically 
children need more food per kilogram of bodyweight 
than do adults.49 Consequently, children are particularly 
susceptible to any growth deﬁ cits caused by infections 
or reduced nutrient intake, and growth-faltering states 
are particularly associated with diseases such as 
HIV/AIDS50 and schistosomiasis;27,51 moreover, these 
infections might have synergistic interactions that 
amplify their individual eﬀ ects.
Drugs are often more widely distributed around 
children’s bodies than in adults and organ blood volumes 
in children are also higher.52 In schistosomiasis, this 
pattern could be highly relevant if blood ﬂ ow to the liver 
is increased, because this diﬀ erence would lead to swift 
clearance of praziquantel and a strong pharmacodynamic 
argument to challenge dosing recommendations directly 
extra polated from adults (ie, 40 mg/kg). Other 
unanswered questions include how HIV infection or 
continuing ART might change praziquantel eﬃ  cacy after 
con sideration that praziquantel’s antischistosomal 
activity is immune-dependent.53 Thus, the context, 
timing, and progression of each infection is important.
HIV precedes schistosomiasis in children
HIV infection in infants and young children is nearly 
always vertically transmitted; thus, HIV infection 
precedes schistosomiasis (ﬁ gure 2), whereas in adult-
acquired infection the reverse is often true (table).54 This 
distinction is very important because the parasitic 
infection (schistosomiasis) in adult-acquired HIV has 
intrinsically diﬀ erent immunopathological and immune-
modulating eﬀ ects, which probably shape the pattern of 
disease. To our knowledge, this concept has not been 
investigated clinically; however, investigators of two 
studies of animals have attempted to assess it for retroviral 
replication and worm reduction after praziquantel 
treatment.38,39 Rhesus macaques carrying a latent chronic 
simian-human immunodeﬁ ciency virus (SHIV) infection 
(in analogy with HIV) were infected with cercariae of 
Schistosoma mansoni and had an increase in SHIV 
Figure 2: Conceptual framework of the epidemiology of HIV and schistosomiasis co-infection, dual treatment, and proposed control with national guidelines 
and interventions
(A) Proposed pathophysiological mechanism of mother-to-child transmission in pregnant women with one infection (HIV) or two infections (HIV and 
schistosomiasis). (B) Antiretroviral therapy (ART) and praziquantel treatment guidelines as recommended by WHO. Solid line indicates continued treatment. Dotted 
line indicates treatment based on CD4 cell count and clinical staging. All HIV-positive pregnant women are encouraged to start ART (even if not indicated on the basis 
of CD4 cell counts) and to continue throughout pregnancy. Children born to women with HIV are to start ART for 6 weeks, irrespective of their HIV status, because it 
is a diﬃ  cult period to ascertain infection, particularly in resource-poor areas. (C) Integrated national control programmes (INCPs) should tailor their eﬀ orts on the 
basis of in-country prevalence. Programmes should use national health policies that include eﬀ orts to control HIV, schistosomiasis, other helminths and neglected 
tropical diseases, and malaria. Diﬀ erent integrated programmes can include those for maternal–child health, transmission, and ecology of transmission that could 
target social and environmental determinants for all diseases (ie, water sanitation, sexual education and womens’ capacity development, and vector control). 
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replication and faster disease pro gression than had 
animals without intestinal schisto somiasis.39 In the other 
study, T-cell-depleted mice infected with S mansoni and 
later treated with two antischistosomal drugs 
(praziquantel and oxamniquine) had little worm clearance 
compared with mice with a healthy immune system,38 
conﬁ rming the important role of host immunity in drug 
action. Thus, if severely immune-suppressed people 
respond to treatment in the same way, particularly people 
with AIDS, then anti schistosomal treatment probably has 
reduced eﬀ ectiveness in co-infection. Although there are 
no studies of people to corroborate this ﬁ nding, serial 
retreatment studies of adults with HIV who were at high 
risk of S mansoni suggest that adults with more years of 
parasite exposure in childhood (hence more potential for 
established antiparasite immune responses) have longer 
infection-free periods after praziquantel treatment.55 
However, because of the scarcity of evidence, such 
generalised conjectures should be viewed with caution 
(appendix pp 2–3).
Schistosomiasis precedes HIV in adults
In endemic areas, as part of daily water contact, 
individuals typically contract schistosomiasis during 
childhood, with subsequent activation of the immune 
system by antigen-speciﬁ c and non-speciﬁ c immuno-
modulation biasing towards a T-helper-cell 2 polarity, 
potentially increasing susceptibility to viral and myco-
bacterial infections. Later HIV infection might also 
change the host–parasite immune balance. Epi demi-
ological studies of adults in the Democratic Republic of 
the Congo, Ethiopia, and Kenya show a decrease in 
schistosome-egg excretion for those who acquired HIV 
later in life.34–36 A fully competent T-cell population might 
be needed to augment schistosome-egg excretion, or 
perhaps worm fecundity, although reports of a cohort 
study in Zimbabwe provided evidence to the contrary.37
Nonetheless children’s expected response to egg 
excretion in the presence of HIV is unknown. Results of 
targeted epidemiological surveys have shown a high 
percentage of the infants and preschool-age children 
assessed were shedding eggs,8,9,22,24,56 but studies have not 
investigated the HIV status of examined children. For 
example, children with lower or intermittent egg output 
might have a very light intensity infection or they might 
have compromised immune systems from HIV infection 
(or other immune deﬁ ciencies), which impairs eﬃ  cient 
egg excretion and, for this reason alone, HIV infection 
should be considered as a possible contributing factor to 
rate of egg excretion.
Eﬀ ect of co-infection on mortality and 
morbidity 
HIV infection remains a major public health threat in 
sub-Saharan Africa with 1·3 million deaths attributed to 
AIDS every year.3 At least 5% of all disability-adjusted 
life-years (DALYs) lost in low-income and middle-
income countries are believed to be due to HIV/AIDS.57 
A drawback of the DALY is that the eﬀ ect of 
comorbidities is overlooked,58 formally restricting the 
scope of health research and intervention programmes. 
The real context of HIV in sub-Saharan Africa is one in 
which children have two or more concurrent parasites 
in addition to their chronic HIV infection. For example, 
results of two paediatric cohort studies in South Africa59 
and Zambia60 identiﬁ ed female sex, young age (younger 
than 2 years), severe wasting, and anaemia as mortality 
risk factors for children with HIV.59,60 Although 
schistosomiasis was not included as a comorbidity in 
either study, it can contribute to wasting and 
anaemia51,61–64 and is present in both countries.65,66 The 
potential detrimental synergy between HIV and 
schistosomiasis will be most severe in early childhood 
due to metabolic insults during key periods of growth 
and development.
Several studies from schistosomiasis-endemic countries 
have shown severe morbidity with end-organ ﬁ brosis in 
children, disorders that were previously thought to be 
clinically relevant only during adulthood.67 Whether co-
infected children are more or less at risk of end-organ 
ﬁ brosis caused by schistosomiasis is unknown, but we 
hypothesise that children with HIV have less ultrasound-
detectable ﬁ brosis but more liver cellular damage, putting 
them at greater risk of liver dysfunction and failure. This 
damage could be caused by T-cell dysregulation, fuelled by 
HIV infection, preceding the onset of schistosomiasis-
related hepatosplenic disease. This progression is, of 
course, not the case in adults, because liver pathology 
caused by schistosomiasis is already underway when HIV 
infection is acquired.68,69 Research to assess the severity of 
schistosomiasis alongside HIV is needed.
Is AIDS linked with schistosomiasis in 
co-endemic areas?
There has been much discussion about whether schisto-
somiasis increases susceptibility to HIV; in Malawi 
where urogenital schistosomiasis is common, an 
increased susceptibility to HIV transmission among 
women has been suggested by the patterns of submucosal 
inﬂ ammation found around parasite eggs in cervico-
vaginal biopsy samples.70,71 Studies in Kenya and Uganda, 
where intestinal schistosomiasis is common, have shown 
immune-modulation of anti-HIV responses in patients 
with schistosomiasis, including decreased production of 
interleukin 4 and interleukin 10 compared with that in 
individuals without HIV,72 and decreased cytolytic CD8 
T-cell response to viral antigens when both HIV infection 
and schistosomiasis were present.73
HIV Schistosomiasis
Adult Older than 14 years Age 2–5 years 
Child Birth or infancy Younger than 2 years 
Table: Common age of primary infection with HIV and schistosomiasis
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The risk of HIV transmission might be increased by 
inﬂ ammation in the female genital tract from urogenital 
schistosomiasis—women in Tanzania and Zimbabwe with 
female genital schistosomiais have an increased age-
adjusted rate of HIV infection compared with those without 
female genital schistosomiais.74–76 The eﬀ ect of maternal 
female genital schistosomiasis on HIV trans mission, 
during parturition for example, is not known. Additionally, 
men with urogenital schistosomiasis in Madagascar had 
substantial damage to their reproductive tracts,77 with 
increased leucocytes and proinﬂ am matory cytokines in 
semen.78 As with other proinﬂ am matory sexually 
transmitted infections, urogenital schisto somiasis in both 
sexes could increase HIV transmission as children enter 
puberty and become sexually active.
Babies of mothers who have both HIV and other 
common helminth infections (lymphatic ﬁ lariasis, 
urogenital schistosomiasis, and hookworm) during 
pregnancy are more likely to have HIV 1 year after birth 
than are babies born to mothers with HIV alone.47 The 
risk of intrauterine, perinatal, or breast-feeding-related 
mother-to-child HIV transmission might be increased by 
substantial immune modulation in utero during the 
development of a doubly exposed fetus, rendering the 
baby more susceptible to viral infections.
A more rapid progression of HIV infection with pre-
existing schistosomiasis seems likely because a 17-times-
lower viral inoculum of SHIV was suﬃ  cient to infect 
rhesus macaques with intestinal schistosomiasis via 
mucosal exposure than the dose needed to infect controls 
without intestinal schistosomiasis.79 In mice, T-regulatory 
cell upregulation, which occurs in schistosomiasis, can 
inhibit the ability of CD8 cells to control viral replication 
and, if similar in human beings, could potentially 
increase HIV progression with concurrent schisto-
somiasis.80 Mice with schisto somiasis have raised 
concentrations of arginase-1 in macrophages; the 
arginase-1 in macrophages and neutrophils in individuals 
with HIV might worsen immune hyporesponsiveness, 
increasing opportunistic infections.81,82 The presence of 
increased HIV receptors on CD4 cells in patients with 
intestinal schistosomiasis creates further opportunity for 
HIV transmission and progression.83
Treatment with praziquantel 
The eﬀ ect of HIV
The eﬀ ectiveness of praziquantel is dependent on 
adequate blood concentrations of the drug and on 
presence of an intact and robust immune system84—
parasitological cure in T-cell-depleted mice with 
intestinal schistosomiasis is decreased compared with 
infected controls.38 Initial action of praziquantel against 
adult worms is associated with tegumental disruption 
and later synergy with an eﬀ ective antibody-mediated 
immune attack.84 By contrast, studies of adults with HIV 
suggest that early immune suppression does not 
adversely aﬀ ect antischistosomal treatment with 
praziquantel, with no diﬀ erence noted in parasitological 
cure rates between patients with HIV and those without 
in Kenya, Zambia, and Zimbabwe (appendix pp 4–5).43,85,86 
However, eﬀ ects of antiparasitic treatment on HIV-
related markers are not clear because a 2009 meta-
analysis showed some beneﬁ t for deworming in the 
prevention of HIV progression after pooling of 
randomised trial data.87 When data for observational 
studies were included in the analysis, the apparent 
deworming eﬀ ect was not as strong.88 Most surprisingly 
perhaps, no study has yet investigated treatment of both 
HIV and schisto somiasis with antiretroviral drugs as 
part of the regimen. In Zimbabwe, an unblinded 
randomised controlled trial showed a decrease in viral 
load and an increase in CD4 cell counts among adults 
who received early praziquantel treatment, compared 
with those who were treated 3 months after diagnosis.89 
Results of a double-blind, placebo-controlled, trial of 
multiple helminth co-infections in a cohort of pregnant 
women in Uganda showed no diﬀ erence in viral load 
between women with HIV given praziquantel and those 
given placebo. However, investigators did report a 
beneﬁ t for patients treated with albendazole for other 
helminth infections, although the prevalence of 
intestinal schistosomiasis in this part of Uganda can be 
considered mild.48 A study in Ethiopia found evidence of 
a relation between deworming and decreased viral 
load.90 Conversely, results from two Ugandan studies 
showed a transient increase in viral load and decreased 
CD4 cell counts after treatment, mainly in individuals 
with severe intestinal schisto somiasis,42,91 from a 
transient host immune activation after praziquantel 
treatment, yielding a situation that favours increased 
viral replication. Other results from Kenya, Malawi, 
Uganda, and Zambia have shown no eﬀ ect of 
praziquantel on HIV viral markers.40,92,93
Use of praziquantel in children
The dosage for praziquantel in children (ie, at 40 mg/kg) 
is a direct extrapolation from adults, and is probably 
ﬂ awed because no information about praziquantel 
pharma cokinetics and pharmacodynamics in young 
children is available. Nonetheless, studies indicate 
eﬃ  cacy and safety on-the-ground with use of a 
praziquantel dosing pole, which allocates treatment on 
the basis of children’s height.9,12,94 However, evidence 
from Uganda95 has raised questions about recom-
mended dosing, which might be inadequate for the 
metabolism of pre-school-age children and about 
whether children’s immune systems are suﬃ  ciently 
developed to provide potent parasite clearance. This 
eﬀ ect on parasite clearance could be worsened by 
concurrent HIV infection or some other congenital or 
acquired immune deﬁ ciency.
Extrapolation of dose by weight from adults is 
particularly problematic because blood volumes, meta-
bolic rates, and extracellular volumes are better correlated 
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with body surface area. As a result, drug doses normalised 
to the weight of adults can result in lower doses in young 
children than when normalised to body surface area.96 
Developmental changes are also important; particularly 
pertinent to praziquantel is the maturation of drug 
metabolism because the fetal liver contains only 30–40% 
of the CYP450 detoxiﬁ cation system content of adults, 
which typically ascends to a peak by age 10 years.97 These 
reduced enzyme concentrations might suggest slower 
drug clearance from the bloodstream in children, which 
is consistent with observations that drug concentrations 
are generally reported as higher in children than in 
adults.98 
An era of community chemotherapy: drug–drug 
interactions
With the roll-out of ART and increasing use of praziquantel 
in early childhood,99 there might be substantial beneﬁ t to 
treat both diseases simultaneously and as early as possible; 
however, some further consideration of drug interactions 
and side-eﬀ ects would be advisable because of the many 
potential interactions between ART drugs and antiparasitic 
drugs. The cytochrome P450 super-family of enzymes is 
central to drug metabolism and drug–drug interactions, 
particularly praziquantel.100 Praziquantel is rapidly 
absorbed and has more than 80% bioavailability after oral 
administration,101 with drug clearance predominantly 
occurring by ﬁ rst-pass meta bolism of CYP1A2, CYP2C19, 
and CYP3A4, with a dominance of CYP3A.102,103 Based on 
knowledge of drug metabolism, the expected eﬀ ects of 
clinicians giving both ART and praziquantel will probably 
diﬀ er dependent on which ART drugs are used. For 
example, decreased praziquantel concentrations could 
occur if given concurrently with non-nucleoside reverse 
tran scriptase inhibitors nevirapine or efavirenz, so-called 
HIV backbone treat ments. These drugs are CYP450 
inducers. Coadmini stration of praziquantel with protease 
inhibitors, which tend to inhibit CYP450 metabolism, 
could lead to increased praziquantel concentrations;104 
thus, well designed studies of paediatric pharmacokinetics 
are needed to ensure safe and eﬀ ective dosing when drugs 
are given concurrently.
Other drugs commonly used in sub-Saharan Africa are 
artemisinin-combination drugs and quinine derivatives 
for malaria, but based on their liver enzyme 
metabolism,105,106 neither is likely to aﬀ ect praziquantel 
metabolism when given concomitantly. Antituberculous 
treatments (rifampicin, isoniazid, and clarithromycin) 
might have an eﬀ ect on circulating praziquantel 
concentrations. Rifampicin is a potent inducer of 
CYP450, particularly CYP2C19 and CYP3A4, and in 
theory, this action could reduce circulating praziquantel 
concentrations.103 Isoniazid and clarithromycin might 
increase praziquantel circulating concentrations.107–109 
Clarithromycin is recommended for multidrug-resistant 
infections.107
Immune reconstitution inﬂ ammatory syndrome
Immune reconstitution inﬂ ammatory syndrome, more 
recently referred to as immune reconstitution disease, is a 
well known disorder that can occur after initiation of ART 
in some individuals. Immune reconstitution disease is a 
collection of inﬂ ammatory disorders associated with 
paradoxical worsening of existing infectious processes, 
particularly opportunistic infections of HIV/AIDS.110 
Clinicians are reporting an increasing number of immune 
reconstitution disease cases in association with parasitic 
diseases, with ﬂ are-ups of reactivating schistosomiasis 
being noted as evidenced by raised eosinophilia, 
hepatosplenomegaly, and colitis with polyposis.45
In Zimbabwe, results of a 2008 study show signiﬁ cant 
decreases in soluble tumour necrosis factor receptor 2 (a 
cytokine-associated marker linked with systemic 
inﬂ ammation) among patients with both HIV and 
schisto somiasis after they were given praziquantel.41 This 
ﬁ nding suggests a reduction in inﬂ ammatory responses 
after praziquantel, which might lead to decreased HIV 
viral replication and even attenuate the risk of immune 
reconstitution disease after ART. Because no studies 
have been carried out in patients given ART, this sphere 
remains to be explored in all age groups.
HIV and schistosomiasis co-infection and 
childhood vaccinations
After the expanded programme of vaccination, global 
vaccine coverage for children is increasing every year,19 
whereas knowledge for the eﬀ ects of coexisting 
childhood morbidities on response to vaccines is lagging 
behind, restricting vaccines’ optimum eﬀ ectiveness in 
on-the-ground settings. Although safe, vaccination in 
children with HIV is less immunogenic than in children 
without HIV,111–113 and children with HIV who do achieve 
protective antibody titres can have a more rapid waning 
of vaccine-induced immunity.114
Children born to women who have parasitic diseases, 
including schistosomiasis, have a decreased response to 
certain childhood vaccinations (eg, BCG115,116). A 2011 
randomised controlled trial in Uganda showed no 
association between single praziquantel or albendazole 
treatment of late-term pregnant women and the response 
of their infants to BCG;117 it is unlikely that one maternal 
dose of praziquantel can erase fetal immune sensitisation 
to schistosome antigens. However, the question remains as 
to whether maternal parasite infection, and then immune-
skewing by HIV, modiﬁ es or exacerbates disease among 
children who then acquire schistosomiasis early in life, and 
whether HIV and schistosomiasis have combined eﬀ ects 
on the eﬃ  cacy of later childhood vaccinations—all of these 
events can also be set against pubertal hormonal production 
and its potential protection against schistosomiasis.118,119
Delineating a research agenda 
As we have stated, there are several gaps in knowledge 
about HIV and schistosomiasis co-infection in children, 
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which is rather staggering. When planning future 
integrated health interventions, we ﬁ rmly believe that 
there is a global duty to address the disparity between 
paediatric and adult research and, as conceptual 
guidance, we suggest a timeline for future paediatric 
HIV and schistosomiasis research, delineated into key 
developmental periods of the child (ﬁ gure 3).
Before birth, there should be better documentation of 
the intricate relation between HIV and concurrent 
helminthiasis in mothers and unborn children, including 
eﬀ orts to develop non-invasive imagery methods or 
assays for detection of female genital schistosomiasis to 
clarify the at-risk population. Pregnant women with 
female genital schistosomiasis should receive 
praziquantel and rates of HIV transmission from treated 
mothers to children should be recorded. The eﬀ ect of 
untreated vertically transmitted HIV in children who 
contract schistosomiasis at an early age should be 
investigated, along with their rate of progression to AIDS. 
The response to immunisation in children co-infected 
with HIV and schistosomiasis should be studied, with 
observation done of children born to women with schisto-
somiasis. Researchers should investigate the extent of 
fetal immune priming and modulation during the 
antenatal period and how this priming aﬀ ects risk of 
schistosomiasis disease and HIV progression later in life.
In children, the timing and successful occurrence of 
key stages as they progressively gain independence from 
their mothers is important. Interactions between HIV 
and schistosomiasis in causative mechanisms of 
anaemia, growth, retardation, decreased cognition, and 
decrease in overall quality of life need to be elucidated. 
Pharmacokinetics and pharmacodynamics of 
praziquantel eﬃ  cacy in children should be investigated 
in ﬁ eld settings, as should drug–drug interactions of 
antiparasitic drugs used in preventive chemotherapy 
alongside ART and antituberculous drugs. 
Investigators should more precisely measure the 
physical changes and psychological challenges to 
attainment of wellbeing for older children and 
adolescents with chronic diseases such as HIV and 
schistosomiasis by doing culturally sensitive studies of 
issues surrounding the beginning of sexual activity and 
minimisation of further risks of HIV transmission. Non-
invasive methods for detection of genital schistosomiasis 
in both sexes and clinical staging schedules for disease 
management are needed. Pubertal hormonal production 
and its potential protection against schistosomiasis 
progression and reinfection rates should be studied. 
Social determinants of health encompassing behavioural 
and psychosocial problems should also be recorded to 
ensure the development and application of tailored 
interventions.
Conclusion 
Provision of optimum public health care for paired 
management of HIV and schistosomiasis in sub-
Saharan Africa might be more than a decade away. 
Failure to develop and implement a realistic research 
Immune responses in children vertically infected with HIV followed by Schistosoma spp infection
Perinatal mortality associated with vertical HIV 
transmission and severe immunosuppression 
with early schistosomiasis
Impaired growth and development;
paediatric quality-of-life assessment;
cognitive performance
Maternal–child HIV
transmission risks
(ie, FGS)
Immune modulations in
fetus from mother with
HIV or schistosomiasis
Evolving PZQ pharmacokinetics and pharmacodynamics and performance;
drug–drug interactions of PZQ with ARVs and antimalarials
Early schistosomiasis disease in children with HIV and HIV-exposed children;
progression to AIDS alongside concurrent schistosomiasis
Response to childhood vaccinations in children with HIV–schistosomiasis
New diagnostic methods for FGS;
psychosocial hurdles aﬀecting ARV
compliance and initiation of sexuality;
interactions with secondary hormones
Prenatal Infants
(birth–12 months)
Preschool-age child
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School-age child
(aged 6–13 years)
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(older than 14 years)
Early interactions 
in infants with HIV 
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Figure 3: Suggested topics for research of paediatric HIV and schistosomiasis infection in dual endemic areas of sub-Saharan Africa
FGS=female genital schistosomiasis. PZQ=praziquantel. ARV=antiretrovirals.
Search strategy and selection criteria
We searched PubMed and Google Scholar for articles 
published from Jan 1, 1990, to July 30, 2013, with use of the 
terms “HIV”, “AIDS”, “schistosomiasis”, “children”, 
“paediatrics”, “Africa”, “morbidity”, and “immunology”. We 
applied additional terms and ﬁ lters for “HIV-schistosomiasis 
co-infection”. From the results of this search, we reviewed 
articles published in English, French, and Spanish. 
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agenda for infected children will result in the neglect of 
the youngest children who might be at particular risk for 
increased HIV transmission, HIV progression, and 
impaired response to drugs. We hope that this Review 
will stimulate a collective agenda to ensure that real 
progress will be made in the long-term management of 
paediatric HIV and schistosomiasis co-infection.
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